Arvinas stock lost half its value Tuesday after the biotech company reported mixed results from its Pfizer-partnered breast cancer drug. Trial results show vepdegestrant, a protein-degrading drug ...

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

Pfizer is paying $650 million in upfront cash and making a $350 million equity investment in Arvinas, with another $1.4 billion in backloaded milestone payments.

Pfizer has revealed that its much-anticipated ... Topline results from the VERITAC-2 study showed that Arvinas-partnered vepdegestrant was able to extend progression-free survival (PFS) compared ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

We recently published a list of 14 Best Affordable Stocks to Buy According to Hedge Funds. In this article, we are going to ...

and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial NEW ...

Medscape Medical News, March 12, 2025 Pfizer-Arvinas' Breast Cancer Treatment Shows Mixed Results in Late-stage Study Pfizer and Arvinas' experimental breast cancer treatment failed to delay the ...

Healthcare & Pharmaceuticalscategory· March 11, 2025 Arvinas shares tumble as breast cancer drug with Pfizer shows mixed results Pfizer and Arvinas' experimental treatment failed to delay ...

Healthcare & Pharmaceuticalscategory· March 11, 2025 Arvinas shares tumble as breast cancer drug with Pfizer shows mixed results Pfizer and Arvinas' experimental treatment failed to delay ...